Among the most overlooked tragedies in psychiatric care is a shortened lifespan — people living with severe mental illness die on average 10–25 years earlier than the general population, largely due to metabolic complications compounded by the very medications keeping their symptoms in check. A growing body of evidence now suggests that GLP-1 receptor agonists, the same drug class behind semaglutide and liraglutide, may offer a meaningful corrective.
This Canadian Psychiatric Association review synthesizes emerging evidence on GLP-1 receptor agonists (GLP-1RAs) as a targeted intervention for antipsychotic-induced weight gain (AIWG) in patients with severe and persistent mental illness (SPMI). Antipsychotics — particularly second-generation agents like olanzapine and clozapine — routinely drive weight gains of 10–15% of body mass within the first year of treatment, sharply elevating risk for insulin resistance, type 2 diabetes, and cardiovascular disease. The review finds that GLP-1RAs produced clinically meaningful reductions in both weight and BMI across studied cohorts without worsening psychotic symptoms. Notably, preliminary signals suggest potential neuroprotective and mood-stabilizing properties, though these remain mechanistically speculative.
What makes this analysis compelling is the population it targets. Behavioural weight-loss interventions — diet counseling, structured exercise programs — consistently underperform in SPMI patients, where cognitive impairment, negative symptoms, and institutional barriers limit adherence. GLP-1RAs sidestep this compliance problem by operating pharmacologically rather than behaviourally. The review sits within a broader research arc: randomized trials in psychiatric populations remain sparse, most data derive from relatively small, short-duration studies, and long-term psychiatric safety data are limited. The additional concern of GLP-1RA-associated nausea potentially destabilizing adherence to antipsychotic regimens warrants closer study. Cost and formulary access remain the dominant real-world obstacle, particularly within universal but restrictive public systems. This is a confirmatory, clinically important synthesis, though a definitive Phase III trial in SPMI populations is still conspicuously absent.